Suppr超能文献

2 型糖尿病治疗后的微生物组变化:系统评价。

Microbiome Changes after Type 2 Diabetes Treatment: A Systematic Review.

机构信息

Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.

Department of Surgery, Medical Academy, Lithuanian University of Health Sciences, LT-50009 Kaunas, Lithuania.

出版信息

Medicina (Kaunas). 2021 Oct 11;57(10):1084. doi: 10.3390/medicina57101084.

Abstract

: Although the role of the gut microbiome in type 2 diabetes (T2D) pathophysiology is evident, current systematic reviews and meta-analyses analyzing T2D treatment mainly focus on metabolic outcomes. The objective of this study is to evaluate the microbiome and metabolic changes after different types of treatment in T2D patients. : A systematic search of PubMed, Wiley online library, Science Direct, and Cochrane library electronic databases was performed. Randomized controlled clinical trials published in the last five years that included T2D subjects and evaluated the composition of the gut microbiome alongside metabolic outcomes before and after conventional or alternative glucose lowering therapy were selected. Microbiome changes were evaluated alongside metabolic outcomes in terms of bacteria taxonomic hierarchy, intestinal flora biodiversity, and applied intervention. : A total of 16 eligible studies involving 1301 participants were reviewed. Four trials investigated oral glucose-lowering treatment, three studies implemented bariatric surgery, and the rest analyzed probiotic, prebiotic, or synbiotic effects. The most common alterations were increased abundance of and parallel to improved glycemic control. Bariatric surgery, especially Roux-en-Y gastric bypass, led to the highest variety of changed bacteria phyla. Lower diversity post-treatment was the most significant biodiversity result, which was present with improved glycemic control. : Anti-diabetic treatment induced the growth of depleted bacteria. A gut microbiome similar to healthy individuals was achieved during some trials. Further research must explore the most effective strategies to promote beneficial bacteria, lower diversity, and eventually reach a non-T2D microbiome.

摘要

尽管肠道微生物群在 2 型糖尿病(T2D)发病机制中的作用已很明显,但目前分析 T2D 治疗的系统评价和荟萃分析主要关注代谢结果。本研究旨在评估 T2D 患者接受不同治疗后微生物组和代谢变化。

系统检索了 PubMed、Wiley online library、Science Direct 和 Cochrane library 电子数据库。选择了在过去五年内发表的随机对照临床试验,这些试验纳入了 T2D 患者,并评估了常规或替代降血糖治疗前后肠道微生物组组成和代谢结果。根据细菌分类层次结构、肠道菌群生物多样性和应用干预措施,评估微生物组变化与代谢结果的关系。

共综述了 16 项符合条件的研究,涉及 1301 名参与者。四项试验研究了口服降血糖治疗,三项研究实施了减肥手术,其余研究分析了益生菌、益生元和合生元的效果。最常见的变化是 和 的丰度增加,同时血糖控制得到改善。减肥手术,特别是 Roux-en-Y 胃旁路手术,导致改变的细菌门种类最多。治疗后多样性降低是最显著的生物多样性结果,与血糖控制改善相关。

抗糖尿病治疗诱导了耗竭细菌的生长。在一些试验中,肠道微生物组类似于健康个体。需要进一步研究以探索最有效的策略来促进有益细菌的生长、降低多样性,最终达到非 2 型糖尿病微生物组的状态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8075/8540512/f5ce14f66c70/medicina-57-01084-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验